arrow
M

Maxwell R. Lloyd

Beth Israel Deaconess Medical Center
H指数:15
被引数:2,434

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

伊帕西替布联合内分泌疗法和CDK4/6抑制剂在HR+/HER2–转移性乳腺癌中的安全性和抗肿瘤活性(TAKTIC):一项单中心、开放标签、1b期临床试验

2026-04-270
PRE
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

NF1基因改变与CDK4/6抑制剂耐药在激素受体阳性转移性乳腺癌中的从临床到基础研究的转化分析

2025-06-270
PRE
A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
2024-05-020
PRE
Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
2024-05-021
PRE
Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib
2022-02-151
PRE
Genomic Characterization of de novo Metastatic Breast Cancer
2021-02-1526
OAAI
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

激素受体阳性转移性乳腺癌患者对细胞周期蛋白依赖性激酶4/6抑制剂的内在和获得性耐药的基因组景观

2020-08-03210
OAAI
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

BRCA1/2突变转移性乳腺癌对PARP抑制剂或铂类化疗耐药的逆转和非逆转机制

2020-05-01116
OAAI
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC)
2020-02-151
PRE
Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER plus ) metastatic breast cancer (MBC) using whole exome sequencing (WES)
2019-02-151
PRE
High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer
2016-07-150
PRE